Form 4: Tempest Therapeutics CFO Nicholas Maestas Acquires 200,000 Stock Options

Tempest Therapeutics' Chief Financial Officer, Nicholas Maestas, was granted 200,000 employee stock options on January 2, 2025.

Summary

• Nicholas Maestas, the Chief Financial Officer of Tempest Therapeutics, Inc., was granted 200,000 employee stock options.
• The options have an exercise price of $0.86 per share.
• The options vest in 48 equal monthly installments starting from January 2, 2025, contingent upon continued service.
• The options expire on January 1, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative sentiment.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The vesting of the stock options is contingent upon the CFO's continued service with the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with company performance and shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard practice for compensating executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 48 months is typical for such grants, encouraging long-term commitment.
• The exercise price of $0.86 is specific to the company's stock price at the time of the grant.

Stakeholder Impact

• The stock option grant incentivizes the CFO to work towards increasing shareholder value.
• The vesting schedule encourages long-term stability in the company's leadership.

Key Dates

Keywords

stock options, employee stock options, executive compensation, insider trading, Tempest Therapeutics, Nicholas Maestas, TPST